Guardant Health Files 8-K: Material Agreement & Equity Sales
Ticker: GH · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1576280
| Field | Detail |
|---|---|
| Company | Guardant Health, Inc. (GH) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2025 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.00001, $600 million, $659.3 million, $490.7 million, $45 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Guardant Health signed a big deal & sold stock, filing 8-K today.
AI Summary
On February 6, 2025, Guardant Health, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the agreement and sales were not provided in this excerpt.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing mentions a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks depending on the specifics not detailed here.
Key Numbers
- 001-38683 — SEC File Number (Identifies the company's filing with the SEC.)
- 45-4139254 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Guardant Health, Inc. (company) — Registrant
- February 6, 2025 (date) — Date of earliest event reported
- 3100 Hanover Street (location) — Principal executive offices address
- Palo Alto, California (location) — Principal executive offices city and state
- 94304 (location) — Principal executive offices ZIP code
FAQ
What is the nature of the material definitive agreement entered into by Guardant Health?
The filing states that Guardant Health, Inc. entered into a material definitive agreement on February 6, 2025, but the specific terms and details of this agreement are not disclosed in this excerpt.
What type of equity securities were sold unregistered?
The filing mentions "Unregistered Sales of Equity Securities" as an item information, but does not specify the type or amount of securities sold.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 6, 2025.
Where are Guardant Health's principal executive offices located?
Guardant Health's principal executive offices are located at 3100 Hanover Street, Palo Alto, California, 94304.
What is Guardant Health's SEC file number?
Guardant Health's SEC file number is 001-38683.
Filing Stats: 1,934 words · 8 min read · ~6 pages · Grade level 15 · Accepted 2025-02-07 06:35:20
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share GH The Nasdaq G
- $600 million — ursuant to which the Company will issue $600 million aggregate principal amount of 1.25% Con
- $659.3 million — nge for the retirement of approximately $659.3 million principal amount of 2027 Notes (the "Tr
- $490.7 million — omary closing conditions, approximately $490.7 million in aggregate principal amount of 2027 N
- $45 million — any intends to repurchase approximately $45 million of shares of its common stock (the "com
- $35 million — tions intends to purchase approximately $35 million of shares of the Company's common stock
- $1,000 — l be 16.0716 shares of common stock per $1,000 principal amount of Notes, which repres
- $62.22 — itial conversion price of approximately $62.22 per share of common stock, which reflec
- $100,000,000 — btedness for borrowed money of at least $100,000,000; and (vi) certain events of bankruptcy,
Filing Documents
- d931211d8k.htm (8-K) — 36KB
- d931211dex101.htm (EX-10.1) — 139KB
- d931211dex991.htm (EX-99.1) — 9KB
- g931211g0207055812383.jpg (GRAPHIC) — 5KB
- 0001193125-25-022242.txt ( ) — 339KB
- gh-20250206.xsd (EX-101.SCH) — 3KB
- gh-20250206_lab.xml (EX-101.LAB) — 17KB
- gh-20250206_pre.xml (EX-101.PRE) — 11KB
- d931211d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Form of Exchange Agreement 99.1 Press release of Guardant Health, Inc., dated February 7, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GUARDANT HEALTH, INC. Date: February 7, 2025 By: /s/ Michael Bell Michael Bell Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)